Apatinib potentiates the therapeutic effect of anti‐PD‐1 in locally advanced head and neck cancers
Oral Diseases · 2024
DOI: 10.1111/odi.14768 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, 2024. Verfasst von Shuli Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University Scho…. Hauptthemen laut MEDLINE: Pyridines, Antibodies, Monoclonal, Humanized, Programmed Cell Death 1 Receptor, Tongue Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China (grant No. 82002862), Young Elite Scientist Sponsorship Program by the China Association for Science and Technolog…, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objectives
Antiangiogenic inhibitors have been shown to synergize with immune checkpoint blockade, but the underlying mechanisms of the synergistic response are not fully understood. Patients and Methods We investigate the impact of VEGFR2 inhibition on tumor‐infiltrating immune cells in vivo and the activity of the combination of apatinib and anti‐PD‐1 in synergistic mouse model of HNSCC. A patient with squamous cell carcinoma of the left tongue with cervical lymph node were received with combined induction treatment of camrelizumab and apatinib to validate the efficacy of neoadjuvant immunotherapy before surgery.
Results
We found that apatinib increased the infiltration of CD8 + T cells and decreased the population of Tregs in a preclinical syngeneic mouse model. The proportions of CD8 + PD1 + T cells were significantly increased in apatinib‐treated tumors. The combined treatment of apatinib and anti‐PD‐1 demonstrated better therapeutic benefit than each treatment alone. The patient with squamous cell carcinoma of the left tongue with cervical lymph node achieved major pathologic response (MPR) after two cycles of combined induction treatment.
Conclusion
Our study demonstrated that apatinib therapy synergized with an anti–PD‐1 antibody in preclinical cancer models and in patient with advanced HNSCC. These results provide a new rationale for advancing this neoadjuvant immunotherapy in large scale of clinical trials of HNSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- National Clinical Research Center for Oral Diseases, Shanghai, China.
- Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China.
- Research Unit of Oral and Maxillofacial Regenerative Medicine, Chinese Academy of Medical Sciences, Shanghai, China.
- Department of Oral Pathology, Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
ORCID-Profile: Chaoji Shi, Jiang Li, Zhiyuan Zhang, Yong Han
Förderung
- National Natural Science Foundation of China (grant No. 82002862), Young Elite Scientist Sponsorship Program by the China Association for Science and Technolog…
- National Natural Science Foundation of China
Zitieren
APA
Liu, S., Zhang, L., Ye, W., Zhou, R., Gu, Z., Shi, C., Xu, S., Li, J., Zhang, Z., & Han, Y. (2024). Apatinib potentiates the therapeutic effect of anti‐PD‐1 in locally advanced head and neck cancers. Oral Diseases. https://doi.org/10.1111/odi.14768
Vancouver
Liu S, Zhang L, Ye W, Zhou R, Gu Z, Shi C, et al. Apatinib potentiates the therapeutic effect of anti‐PD‐1 in locally advanced head and neck cancers. Oral Diseases. 2024. doi:10.1111/odi.14768
BibTeX
@article{Liu2024,
author = {Liu, Shuli and Zhang, Lin and Ye, Weimin and Zhou, Rong and Gu, Ziyue and Shi, Chaoji and Xu, Shengming and Li, Jiang and Zhang, Zhiyuan and Han, Yong},
title = {Apatinib potentiates the therapeutic effect of anti‐PD‐1 in locally advanced head and neck cancers},
journal = {Oral Diseases},
year = {2024},
doi = {10.1111/odi.14768}
}
EUVIMED